This is the limited version of the Proteolix company profile: Join LinkedIn or Sign In to see more information.
Proteolix, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. Its products include carfilzomib, which is delivered intravenously; and proteasome inhibitors, including an oral proteasome inhibitor and immunoproteasome inhibitor. The company was founded in 2003 and is headquartered in San Francisco, California.
Your Connections to Proteolix
Popular Profiles at Proteolix
333 Allerton Avenue
South San Francisco, CA
94080
United States
Phone: 650-266-2600
Fax: 650-266-2601
| Top Schools |
| Univ. of California, Berkeley | 6% |
| San Francisco St. Univ. | 5% |
| Stanford Univ. | 5% |
| Univ. of California, Davis | 5% |
| Univ. of California, San Diego | 5% |
|
Estimated based on LinkedIn Data
Career path for Proteolix employees
News about Proteolix
-
From: | November 10, 2009
-
From: | November 10, 2009
In partnership with 
Send feedback on BusinessWeek/CapIQ content to linkedinissues@capitaliq.com. Copyright © 2009 Capital IQ.
This LinkedIn Company Profile was created by LinkedIn and is about Proteolix. This page is not endorsed by or affiliated with Proteolix. For questions regarding LinkedIn Company Profiles, contact us.
| 